Citations

Clear

6274 citation(s) found for "To, Andrew".

Modification of social determinants of health by critical illness and consequences of that modification for recovery: an international qualitative study
McPeake, Joanne , Boehm, Leanne M. , Hibbert, Elizabeth , Hauschildt, Katrina , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , McCartney, Judith, Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Haines, Kimberley , Quasim, Tara , Mikkelsen, Mark E.

Mayo Clinic

BMJ Open | September 27, 2022 | Volume: 12 | Issue: 9 | Pages: e060454

10.1136/bmjopen-2021-060454 | PMID 36167379 Get It

Objectives Social determinants of health (SDoH) contribute to health outcomes. We identified SDoH that were modified by critical illness, and the effect of such modifications on recovery from critical illness. Design In-depth semistructured interviews following hospital discharge. Interview transcripts were mapped against a pre-existing social policy framework: money and work; skills and education; housing, transport and neighbourhoods; and family, friends and social connections. Setting 14 hospital sites in the USA, UK and Australia. Participants Patients and caregivers, who had been admitted to critical care from three continents. Results 86 interviews were analysed (66 patients and 20 caregivers). SDoH, both financial and non-financial in nature, could be negatively influenced by exposure to critical illness, with a direct impact on health-related outcomes at an individual level. Financial modifications included changes to employment status due to critical illness-related disability, alongside changes to income and insurance status. Negative health impacts included the inability to access essential healthcare and an increase in mental health problems. Conclusions Critical illness appears to modify SDoH for survivors and their family members, potentially impacting recovery and health. Our findings suggest that increased attention to issues such as one’s social network, economic security and access to healthcare is required following discharge from critical care.
Quality Indicators for Capsule Endoscopy and Deep Enteroscopy
Leighton, Jonathan A. , Brock, Andrew, Semrad, Carol E. , Hass, David J., Guda, Nalini M. , Barkin, Jodie A. , Eisen, Glenn M.

Mayo Clinic

American Journal of Gastroenterology | September 26, 2022 | Volume: 117 | Issue: 11 | Pages: 1780-1796

10.14309/ajg.0000000000001903 | PMID 36155365 Get It

INTRODUCTION: Capsule endoscopy (CE) and deep enteroscopy (DE) can be useful for diagnosing and treating suspected small-bowel disease. Guidelines and detailed recommendations exist for the use of CE/DE, but comprehensive quality indicators are lacking. The goal of this task force was to develop quality indicators for appropriate use of CE/DE by using a modified RAND/UCLA Appropriateness Method. METHODS: An expert panel of 7 gastroenterologists with diverse practice experience was assembled to identify quality indicators. A literature review was conducted to develop a list of proposed quality indicators applicable to preprocedure, intraprocedure, and postprocedure periods. The panelists reviewed the literature; identified and modified proposed quality indicators; rated them on the basis of scientific evidence, validity, and necessity; and determined proposed performance targets. Agreement and consensus with the proposed indicators were verified using the RAND/UCLA Appropriateness Method. RESULTS: The voting procedure to prioritize metrics emphasized selecting measures to improve quality and overall patient care. Panelists rated indicators on the perceived appropriateness and necessity for clinical practice. After voting and discussion, 2 quality indicators ranked as inappropriate or uncertain were excluded. Each quality indicator was categorized by measure type, performance target, and summary of evidence. The task force identified 13 quality indicators for CE and DE. DISCUSSION: Comprehensive quality indicators have not existed for CE or DE. The task force identified quality indicators that can be incorporated into clinical practice. The panel also addressed existing knowledge gaps and posed research questions to better inform future research and quality guidelines for these procedures.
Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed inflammation
Bowen, Andrew J. , Ekbom, Dale C. , Hunter, Danielle E., Voss, Stephen G. , Mearns‐Spragg, Andrew , Oldenburg, Michael , San‐Marina, Serban , Hunter, Danielle, Voss, Stephen , Oldenburg, Michael S , San-Marina, Serban , Bowen, Andrew Jay , Bartemes, Kathleen R.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | September 24, 2022 | Volume: 7 | Issue: 5 | Pages: 1513-1520

10.1002/lio2.924 | PMID 36258863 Get It

AbstractObjectives/HypothesisCompare proteomic profiles of rabbit vocal folds (VFs) injected with micronized cross‐linked jellyfish collagen “collagen Type 0” (MX‐JC) against two clinical products for injection medialization laryngoplasty (IL).Study DesignAnimal model.MethodsLeft recurrent laryngeal nerve sectioning and IL were performed in New Zealand White rabbits (N = 6/group). Group 1 received (MX‐JC) and adipose‐derived stem cells (ADSCs), Group 2, MX‐JC alone; Group 3, cross‐linked hyaluronic acid; and Group 4, micronized acellular dermis. Animals were sacrificed at 4 and 12 weeks. Proteomic profiling of injected versus noninjected VFs by nano‐liquid chromatography, tandem mass spectrometry, and reactome gene ontology analysis was performed.ResultsOverall, 37–61 proteins were found to be upregulated and 60–284 downregulated in injected versus non‐injected VFs (>1.5 fold, false discovery rate‐adjusted p < .05). Over‐representation analysis (% of total) revealed top up‐regulated pathways at 4 and 12 weeks, respectively: Group 1, keratan sulfate metabolism (46%) and cellular processes (29%); Group 2, extracellular matrix (ECM)/collagen processes (33%) and beta oxidation (39%); Group 3, cellular processes (50%) and energy metabolism (100%); and Group 4, keratan sulfate metabolism (31%) and inflammation (50%). Top downregulated pathways were: Group 1, Inflammation (36%) and glucose/citric acid metabolism (42%); Group 2, cell signaling (38%) and glucose/citric acid metabolism (35%); Group 3, keratan sulfate metabolism (31%) and ECM/collagen processes (48%); and Group 4, glucose/citric acid metabolism (33%) and ECM/collagen processes (43%).ConclusionsMX‐JC “collagen Type 0” upregulates pathways related to ECM/collagen formation and downregulates pathways related to inflammation suggesting that it is promising biomaterial for IL.Level of EvidenceNA
Evaluation of Treatment Effect in Underrepresented Population in Cancer Trials: Discussion with International Regulators
Sridhara, Rajeshwari , Marchenko, Olga , Barksdale, Elizabeth , Gwise, Thomas, Hess, Lorenzo , Mandrekar, Sumithra J. , Rantell, Khadija , Raven, Andrew, Shen, Yuan-Li, Tendler, Craig , Theoret, Marc R. , Jiang, Qi , Chen, Jie , Dreyer, Nancy A , Fashoyin-Aje, Lola , Garrett‐Mayer, Elizabeth , Gormley, Nicole , Pignatti, Francesco , Raven, Andrew, Singh, Harpreet, Pazdur, Richard M.

Mayo Clinic

Statistics in Biopharmaceutical Research | September 23, 2022 | Volume: 15 | Issue: 2 | Pages: 450-456

10.1080/19466315.2022.2128404 Get It

Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database Study
Yee, Timothy J., Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Haid, Regis W., Park, Paul

Mayo Clinic

Neurosurgery | September 23, 2022 | Volume: 91 | Issue: 6 | Pages: 952-960

10.1227/neu.0000000000002161 | PMID 36149088 Get It

BACKGROUND: The modified Japanese Orthopedic Association (mJOA) score is a widely used and validated metric for assessing severity of myelopathy. Its relationship to functional and quality-of-life outcomes after surgery has not been fully described. OBJECTIVE: To quantify the association of the mJOA with the Neck Disability Index (NDI) and EuroQol-5 Dimension (EQ-5D) after surgery for degenerative cervical myelopathy. METHODS: The cervical module of the prospectively enrolled Quality Outcomes Database was queried retrospectively for adult patients who underwent single-stage degenerative cervical myelopathy surgery. The mJOA score, NDI, and EQ-5D were assessed preoperatively and 3 and 12 months postoperatively. Improvement in mJOA was used as the independent variable in univariate and multivariable linear and logistic regression models. RESULTS: Across 14 centers, 1121 patients were identified, mean age 60.6 ± 11.8 years, and 52.5% male. Anterior-only operations were performed in 772 patients (68.9%). By univariate linear regression, improvements in mJOA were associated with improvements in NDI and EQ-5D at 3 and 12 months postoperatively (all P < .0001) and with improvements in the 10 NDI items individually. These findings were similar in multivariable regression incorporating potential confounders. The Pearson correlation coefficients for changes in mJOA with changes in NDI were −0.31 and −0.38 at 3 and 12 months postoperatively. The Pearson correlation coefficients for changes in mJOA with changes in EQ-5D were 0.29 and 0.34 at 3 and 12 months. CONCLUSION: Improvements in mJOA correlated weakly with improvements in NDI and EQ-5D, suggesting that changes in mJOA may not be a suitable proxy for functional and quality-of-life outcomes.
Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
Veer, Rozanne C. de , Harms, Maren H. , Thorburn, Douglas , Janssen, Harry L.A. , Nevens, Frederik , Lindor, Keith D. , Floreani, Annarosa , Ponsioen, Cyriel Y. , Mayo, Marlyn J. , Parés, Albert , Mason, Andrew L. , Bruns, Tony , Buuren, Henk R. van , Meer, Adriaan J. van der, Group, the Global PBC Study, van der Meer, Adriaan J , Invernizzi, Pietro , Lindor, K D , Mayo, Marlyn J , Mason, Andrew , Hirschfield, Gideon M , Bruns, Tony , Verhelst, Xavier , Corpechot, Christophe , Invernizzi, Pietro , Battezzati, Pier Maria , Kowdley, Kris V. , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Dalekos, George Ν. , Gatselis, Nikolaos , Verhelst, Xavier , Lammers, Willem J. , Hansen, Bettina E. , Meer, Adriaan J. van der, Group, the Global PBC Study

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 23, 2022 | Volume: 56 | Issue: 9 | Pages: 1408-1418

10.1111/apt.17226 | PMID 36138566 Get It

SummaryBackgroundAfter 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels.AimTo assess the association between ALP and liver transplantation (LT)‐free survival according to the GLOBE scoreMethodsAmong patients with a normal or elevated GLOBE score in the Global PBC cohort, the association between ALP after 1 year of UDCA and the risk of LT/death was assessed. The LT‐free survival was compared with that of a matched general population.ResultsAfter 1 year of UDCA, ALP was associated with the risk of LT/death (aHR 1.31, 95% CI 1.003–1.72, p = 0.048) among 2729 patients with a normal GLOBE score. The 10‐year LT‐free survival among these patients with an ALP >2.0 × ULN was 94.0% (95% CI 90.1–97.9) for those <50 years, and 82.6% (95% CI 76.5–88.7) for those ≥50 years, which was significantly lower (p = 0.040) and similar (p = 0.736) to that of the matched population, respectively. The 10‐year LT‐free survival in patients ≥50 years with normal GLOBE score and normal ALP (90.8%, 95% CI 87.7–93.9) was significantly higher (p = 0.022) than the matched population. Among 1045 patients with an elevated GLOBE score, ALP was associated with LT/death only in those <50 years (aHR 1.38, 95% CI 1.06–1.81, p = 0.016).ConclusionThe LT‐free survival of patients with PBC with a normal GLOBE score is optimal in case of normal ALP levels, also in relation to the general population. Despite their generally favourable prognosis, an elevated ALP level may still indicate a need for add‐on therapy.
Peripheral artery disease and the risk of venous thromboembolism
Sykora, Daniel , Firth, Christine , Girardo, Marlene , Bhatt, Shubhang K. , Liedl, David , Wennberg, Paul W. , Shamoun, Fadi , Bhatt, Shubhang, Tseng, Andrew , Chamberlain, Alanna, Wennberg, Paul, Shamoun, Fadi Elias , Tseng, Andrew S. , Chamberlain, Alanna M.

Mayo Clinic

Vasa | September 22, 2022 | Volume: 51 | Issue: 6 | Pages: 365-371

10.1024/0301-1526/a001029 | PMID 36134738 Get It

Summary: Background: Peripheral artery disease (PAD) impacts 3–12% of patients worldwide and is characterized by endothelial dysfunction and inflammatory pathways which are also common to venous thromboembolism (VTE), but there is a paucity of evidence regarding VTE risk in PAD patients. We investigated whether PAD is an independent risk factor for VTE. Patients and methods: We reviewed medical records of patients undergoing ABI studies at Mayo Clinic from 01/1996-02/2020. We classified patients by ABI (low [<1.0], normal [1.0–1.4], or elevated [>1.4]), as well as by specific low ABI subgroup: severely reduced (ABI: 0.00–0.39), moderately reduced (0.40–0.69), mildly reduced (0.70–0.90), and borderline reduced (0.91–0.99). The primary outcome was incident VTE event (acute lower extremity deep vein thrombosis or pulmonary embolism) after ABI measurement. Multivariable Cox proportional regression was used to calculate hazard ratios (HR) with 95% confidence intervals (CI) after adjusting for age, sex, active smoking, cancer, previous VTE, thrombophilia, anticoagulation, and revascularization. Results: 39,834 unique patients (mean age 66.3±14.3 years, median follow-up 34 months) were identified. 2,305 VTE events occurred in patients without PAD (13.0%), 2,218 in low ABI patients (13.0%), and 751 in elevated ABI patients (14.8%). After risk factor adjustment, VTE risk was modestly increased for PAD overall (HR: 1.12, 95% CI [1.06, 1.18]), including low ABI (HR: 1.11, 95% CI [1.04, 1.18]) and elevated ABI groups (HR: 1.15, 95% CI [1.04, 1.26]), compared to patients without PAD. The greatest VTE risk was in severely low ABI patients (HR: 1.46, 95% CI [1.31, 1.64]). Conclusions: In a large longitudinal cohort, we present strong clinical evidence of PAD, with low and elevated ABI, as an independent VTE risk factor, with the highest risk seen in patients with severely low ABI. Continued research is required to further investigate this relationship and its intersection with functional performance status to optimize VTE risk reduction or anticoagulation strategies in the PAD population.
P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202
Sahai, Vaibhav , Vaccaro, Gina M. , Rajabi, Raed MAl, Paulson, Andrew Scott , Gallinson, David, Oh, Do‐Youn , Catenacci, Daniel V.T. , Lihou, Christine , Véronèse, L., Sahai, Vaibhav , Vogel, Arndt , Hollebecque, Antoine , Melisi, Davide , Borad, Mitesh J. , Murphy, Adrian , Dotan, Efrat , Cutsem, Eric Van , Zhen, Huiling, Abou‐Alfa, Ghassan K.

Mayo Clinic

Abstracts | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A44.1-A44

10.1136/gutjnl-2022-basl.69 Get It

P09 Long-term obeticholic acid (OCA) for Primary Biliary Cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
Perez, Carla , Adekunle, Femi, Mayne, Tracy J. , Malecha, Elizabeth Smoot, Ness, Eric , Meer, Adriaan J Van Der, Nevens, Frederik , Bruns, Tony , Floreani, Annarosa , Mayo, Marlyn J. , Thorburn, Douglas , Gulamhusein, Aliya , Bowlus, Christopher L. , Lindor, Keith D. , Bruns, Tony , Bowlus, Christopher L , Meer, Adriaan van der , Lammers, Willem J. , Trivedi, Palak Jitendrakumar , Battezzati, Pier Maria , Kowdley, Kris V. , Cazzagon, Nora , Mason, Andrew L. , Parés, Albert , Londoño, Maria, Invernizzi, Pietro , Carbone, Marco , Lleò, Ana , Dalekos, George Ν. , Gatselis, Nikolaos , Verhelst, Xavier , Janssen, Harry L.A. , Trauner, Michael , Corpechot, Christophe , Hirschfield, Gideon M. , Hansen, Bettina E.

Mayo Clinic

Abstracts | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A37-A37

10.1136/gutjnl-2022-basl.60 Get It